GO
Loading...

Actavis Inc

More

  • Actavis to buy Forest Labs; windfall for Icahn Tuesday, 18 Feb 2014 | 10:57 AM ET

    Actavis agreed to acquire rival drug maker Forest Laboratories in a deal worth as much as $25 billion.

  • *Forest Labs surges after Actavis confirms acquisition. NEW YORK, Feb 18- U.S. stocks were little changed on Tuesday after Wall Street's biggest gain of the year as disappointing economic reports weighed on investor sentiment.

  • Feb 18- Generic drugmaker Actavis Plc said on Tuesday it would buy Forest Laboratories Inc for about $25 billion in cash and stock, expanding its portfolio of specialty pharmaceuticals for neurological and other disorders. Actavis said it would pay the equivalent of $89.48 per share, representing a premium of 25 percent to Forest's closing price on Friday.

  • *Forest Labs surges after Actavis confirms acquisition. *Shares of Forest Laboratories Inc rocketed more than 35 percent in premarket trading after Actavis said it would acquire the specialty pharmaceuticals company in a massive cash and stock deal valued at about $25 billion.

  • Feb 18- Actavis Plc is in advanced talks to acquire rival drug maker Forest Laboratories Inc in a deal that could value Forest at up to $25 billion, the Wall Street Journal reported citing people familiar with the matter. Actavis competes with larger drugmakers such as Teva Pharmaceuticals Industries Ltd and Mylan Inc..

  • Feb 17- Actavis Plc is in advanced talks to acquire rival drug maker Forest Laboratories Inc in a deal that could value Forest at up to $25 billion, the Wall Street Journal reported citing people familiar with the matter. The deal is expected to be announced as early as Tuesday, but it is possible that the talks could still fall apart, the Journal said.

  • Early movers: JPM, TWC, GOOG, AAPL, MSFT, & more Tuesday, 14 Jan 2014 | 7:51 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • New way to cut your taxes: Merge overseas Wednesday, 9 Oct 2013 | 11:20 AM ET
    Japan's Tokyo Electron chairman Tetsuro Higashi (L) shakes hands with US semiconductor giant Applied Materials CEO Gary Dickerson (R) after they agreed to merge, at a press conference in Tokyo on September 24, 2013.

    More large American corporations are reducing their tax bill by buying a foreign company and effectively renouncing their United States citizenship.

  • Amgen to buy Onyx for more than $10 billion Monday, 26 Aug 2013 | 7:51 AM ET

    Amgen has struck a $10 billion-plus deal to buy Onyx Pharmaceuticals, ending a two-month-long auction for the cancer drugmaker.

  • Delivering Alpha: 2012's best and worst ideas Friday, 28 Jun 2013 | 9:36 AM ET

    Hedge fund titan Leon Cooperman came up with 10 ideas last year and all of the stocks have delivered returns. Will anybody at this year's Delivering Alpha conference match his record?

  • The report card on hedge fund boss Leon Cooperman Thursday, 27 Jun 2013 | 12:23 PM ET
    Leon Cooperman, chairman of Omega Advisors

    Check out last year's top 10 picks from Omega Advisors founder Leon Cooperman and guess what you find? A 31 percent return.

  • Cramer: Big Winners to Gain into Quarter's End? Thursday, 20 Jun 2013 | 6:29 PM ET

    As the quarter draws to a close, Jim Cramer thinks 5 stocks could attract new buyers.

  • Cramer Makes the Case for M&A Monday, 17 Jun 2013 | 6:58 PM ET

    Cramer gives three reasons why companies should consider mergers and acquisitions.

  • High Court's Generic Drug Ruling 'a Holy Mess' Monday, 17 Jun 2013 | 3:58 PM ET
    Supreme Court Justice Stephen Breyer

    A Supreme Court decision gives the FTC the go-ahead to continue suing drug makers over deals that delay generic versions from being sold.

  • Two Global Companies Just Moved for Tax Reasons Wednesday, 22 May 2013 | 5:41 AM ET

    Even as Apple faced a grilling from lawmakers over its tax avoidance schemes, two more companies revealed they would move jurisdictions to lighten their tax burden.

  • Stocks End Lower; Dow, S&P Briefly Hit New Highs Monday, 20 May 2013 | 4:27 PM ET

    Stocks closed slightly lower in choppy trading Monday, pulling back after the Dow and S&P 500 hit fresh all-time highs and amid ongoing worries that the Federal Reserve may taper its bond-purchase program.

  • Futures Slide Amid Fed Easing Fears Monday, 20 May 2013 | 8:48 AM ET

    U.S. stock market index futures were slightly lower Monday, after major averages finished higher for the fourth-consecutive week, amid ongoing concerns the Federal Reserve may begin to taper off its quantitative easing program sooner than expected.

  • Actavis to Buy Warner Chilcott for $8.5 Billion Monday, 20 May 2013 | 8:11 AM ET
    Warner Chilcott Ltd.'s acne treatment Doryx.

    Generic drugmaker Actavis will buy specialty pharmaceuticals company Warner Chilcott in a stock deal valued at about $8.5 billion.

  • Early Movers: WMT, KSS, CSCO & More Thursday, 16 May 2013 | 7:33 AM ET

    Some of the names on the move ahead of the open.

  • Actavis Rejects $15 Billion Bid From Mylan: Report Wednesday, 15 May 2013 | 7:43 AM ET

    Actavis received and rejected a takeover offer from Mylan last week that valued the generic drugmaker at more than $15 billion, a person familiar with the situation said.